IN THE CLAIMS:

Kindly amend Claims 1, 3, 5, 8, 9 and 14 as follows:

1. (currently amended) A monocyclic compound having the formula (1):




in which:

$X_1$, $X_2$, $X_3$, $X_4$, which may be the same or different from one another, is selected from the group consisting of -CONR-, -NRCO-, -OCO-, -COO-, $-CH_2NR-$ and $-NR-CH_2-$, where R is H or a $C_{1-3}$ alkyl or benzyl;

f, g, h, m, which may be the same or different from one another, may be 0 or 1;

$R_1$ and $R_2$ which may be the same or different from one another, represent the side chain of a natural amino acid selected from the group consisting of tryptophan, phenylalanine, tyrosine and histidine, or the side chain

of a non-natural amino acid selected from the group consisting of:

tryptophan and phenylalanine, either mono- or di-substituted with residues selected from the group consisting of $C_{1-3}$ alkyl or halo-alkyl, $C_{1-3}$ alkoxyl or amino-alkoxyl, halogen, OH, $NH_2$ and $NR_{13}R_{14}$, where $R_{13}$ and $R_{14}$, which may be the same or different from one another, represent a hydrogen or $C_{1-3}$ alkyl group;

$R_3$ is selected from the group consisting of:

- linear or branched alkyl having the formula $C_nH_{2n+1}$ with n=1-5 (selected from the group consisting of methyl, ethyl, propyl, isopropyl, n-butyl and t-butyl) cycloalkyl or alkylcycloalkyl of formula $C_nH_{2n-1}$ with n=5-9 (selected from the group consisting of: cyclopentyl, cyclohexyl and methylcyclohexyl)

$-(CH_2)_r-Ar_1$, where r=1 or 2 and where $Ar_1$ is an aromatic group selected from the group consisting of: α-naphthyl, β-naphthyl, phenyl, indole, said $Ar_1$ group being possibly substituted with a maximum of two residues selected from the group consisting of: $C_{1-3}$ alkyl, $CF_3$, $C_{1-3}$ alkoxyl, Cl, F, OH and $NH_2$;

$R_4$ represents an L-Q group where:

L is a chemical bond ~~of~~ or $CH_2$, and

Q is selected from the group consisting of:

- OH, $NH_2$, $NR_9R_{10}$, $OR_{11}$, and where $R_9$ and $R_{10}$, which may be the same or different from one another, represent a hydrogen or $C_{1-3}$alkyl group, $C_{1-3}$hydroxy alkyl, $C_{1-3}$dihydroxyaklyl, $C_{1-3}$alkyl-$CONHR_{12}$ (wherein $R_{12}$ is a monoglycosidic group derived from D or L pentoses or hexoses (selected from the group consisting of ribose, arabinose, glucose, galactose, fructose, glucosamine, galactosamine N-acetylglucosamine and

N-acetylgalactosamine)), $C_{1-3}$alkyltetrazole, $C_{1-3}$alkyl-COOH or wherein $R_9R_{10}$ are joined together to form with the N atom a morpholine or a piperidine ring and where $R_{11}$ is a $C_{1-3}$ alkyl chain, or a $C_{2-4}$ amino-alkyl chain;
$NHCOR_8$ wherein $R_8$ is a cyclohexane containing from 2 to 4 OH groups, $C_{1-6}$ alkyl chain containing a polar group (chosen in the group consisting of $NH_2$, COOH, $CONHR_{12}$, (wherein $R_{12}$ is as hereabove defined) or [1,4']bipiperidine))
- COOH, $COOR_{17}$ or $CONHR_{12}$, wherein $R_{12}$ is as hereabove defined and $R_{17}$ is as $R_{12}$ or a group 4-nitrobenzyl
- $R_5$, $R_6$, $R_7$ are [[$H_2$]] H in which the carbon atom that carries the substituents $R_3$ and $R_7$ has configuration R;
wherein when $R_1$=$R_2$= a side chain of ~~trytophan~~ tryptophan and $R_4$= $CH_2OH$ then $R_3$ is not isopropyl.

2. (canceled)

3. (previously amended) A compound according to Claim 1 selected from:

(a) Cyclo{-Suc-Trp-Phe-[(R)-NH-CH($CH_2C_6H_5$)-$CH_2$-NH]}
(b) Cyclo{-Suc-Trp-Phe-[(S)-NH-CH($CH_2C_6H_5$)-$CH_2$-NH]}
(c) Cyclo{-Suc-Trp-Phe-[(R)-NH-CH($CH_2C_6H_{11}$)-$CH_2$-NH]}
(d) Cyclo{-Suc-Trp-Phe-[(R)-NH-CH($CH_2C_6H_4$(4-$OCH_3$))-$CH_2$-NH]}
(e) Cyclo{-Suc-Trp(5F)-Phe-[(R)- NH-CH($CH_2C_6H_5$)-$CH_2$-NH]}
(f) Cyclo{-Suc-Trp(Me)-Phe-[(R)- NH-CH($CH_2C_6H_5$)-$CH_2$-NH]}
(g) Cyclo{-Suc-Phe(3,4-Cl)-Phe-[(R)- NH-CH($CH_2C_6H_5$)-$CH_2$-NH]}
(h) Cyclo{-Suc-Trp-Phe(3,4-Cl)-[(R)- NH-CH($CH_2C_6H_5$)-$CH_2$-NH]}
(i) Cyclo{-Suc-Trp-Tyr-[(R)-NH-CH($CH_2C_6H_5$)-$CH_2$-NH]}
(j) Cyclo{-Suc-Trp-Phe-[(R)-NH-CH($CH_2C_6H_3$-3,4-diCl)-$CH_2$-NH]}
(k) Cyclo{-Suc-Trp-Phe-[(R)-NH-CH($CH_2C_6H_4$-4-OH)-$CH_2$-NH]}
(l) Cyclo{-Suc-Trp-Phe-[(R)-NH-CH($CH_2$-$CH_2$-$C_6H_5$)-$CH_2$-NH]}
(m) Cyclo{-Suc-Trp-Phe-[(R)-NH-CH($CH_2$-2-napthyl)-$CH_2$-NH]}
(n) Cyclo{-Suc-Trp-Phe-[(R)-NH-CH($CH_2$-indol-3-yl)-$CH_2$-NH]}

(o) Cyclo{-Suc-Trp-Phe-[(R)-NH-CH($CH_2$-5-F-indol-3-yl)-$CH_2$-NH]}

(p) Cyclo{-Suc-Trp-Phe-[(R)-NH-CH($CH_2$-$C_6H_4$-3-F)-$CH_2$-NH]}

(q) Cyclo{-Suc-Trp-Phe-[(R)-NH-CH($CH_2$-$C_6H_3$-3,4-diF-$CH_2$-NH]-}

(r) Cyclo{-Suc-Trp-Phe-[(R)-NH-CH($CH_2$-$C_6H_4$-4-$CF_3$-$CH_2$-NH]-}

(s) Cyclo{-Suc-Trp-Phe-[(R)-NH-$CH_2$-CH($CH_2C_6H_5$)-NH]}

(t) Cyclo{-Suc-Trp-Phe-[(S)-NH- $CH_2$-CH($CH_2C_6H_5$)-NH]}

(u) Cyclo{-Trp-Phe-[(R)-NH-CH($CH_2$-$C_6H_5$)-$CH_2$-NH]-$(CH_2)_3$CO-}

(v) Cyclo{-Trp-Phe-[(R)-NH-CH($CH_2$-$C_6H_5$)-$CH_2$-N($CH_3$)]-$(CH_2)_3$CO-}

(w) Cyclo{-Suc[1(S)-$NH_2$]-Trp-Phe-[(R)NH-CH($CH_2$-$C_6H_5$)-$CH_2$NH]-}

(x) Cyclo{-Suc[1(R)-$NH_2$]-Trp-Phe-[(R)NH-CH($CH_2$-$C_6H_5$)-$CH_2$NH]-}

(y) Cyclo{-Suc[2(S)-$NH_2$]-Trp-Phe-[(R)NH-CH($CH_2$-$C_6H_5$)-$CH_2$NH]-}

(z) Cyclo{-Suc[2(R)-$NH_2$]-Trp-Phe-[(R)NH-CH($CH_2$-$C_6H_5$)-$CH_2$NH]-}

(aa) Cyclo{-Suc[1(S)-NH($CH_3$)]-Trp-Phe-[(R)NH-CH($CH_2$-$C_6H_5$)-$CH_2$NH]-}

(ab) Cyclo{-Suc[1-COO($CH_2$-$C_6H_4$-4-$NO_2$)]-Trp-Phe-[(R)NH-CH($CH_2$-$C_6H_5$)-$CH_2$NH]-}

(ac) Cyclo{-Suc(1-COOH)-Trp-Phe-[(R)-NH-CH($CH_2$-$C_6H_5$)-$CH_2$-NH]}

[Cyclo{-Suc(1-COOH)-Trp-Phe-[(R)-NH-CH($CH_2$-$C_6H_5$)-$CH_2$-NH]}]

(ad) Cyclo{-Suc(1-OH)-Trp-Phe-[(R)-NH-CH($CH_2$-$C_6H_5$)-$CH_2$-NH]}

(ae) Cyclo{-Suc(2-COOH)-Trp-Phe-[(R)-NH-CH($CH_2$-$C_6H_5$)-$CH_2$-NH]}

(af) Cyclo{-Suc(2-OH)-Trp-Phe-[(R)-NH-CH($CH_2$-$C_6H_5$)-$CH_2$-NH]}

(ag) Cyclo{-Suc[1(S)-(2H-tetrazolyl-5-ylmethyl)amino]-Trp-Phe-[(R)-NH-CH($CH_2$-$C_6H_5$)-$CH_2$-NH]-} trifluoroacetic acid

(ah) Cyclo{-Suc[1(S)-(morpholin-4-yl)]-Trp-Phe-[(R)-NH-CH($CH_2$-$C_6H_5$)-$CH_2$-NH]-} trifluoroacetic acid

(ai) Cyclo{-Suc[1(S)-$N(CH_3)_2$]-Trp-Phe-[(R)-NH-CH($CH_2$-$C_6H_5$)-$CH_2$-NH]-} trifluoroacetic acid

(aj) Cyclo{-Suc[1(S)-(piperidin-4-yl]-Trp-Phe-[(R)-NH-CH($CH_2$-$C_6H_5$)-$CH_2$-NH]-} trifluoroacetic acid

(ak) Cyclo{-Suc[1(S)-($N(CH_2CH_2OH)_2$)]-Trp-Phe-[(R)-NH-CH($CH_2$-$C_6H_5$)-$CH_2$-NH]} trifluoroacetic acid

(al) Cyclo{-Suc[1(S)-($N(CH_2CH(OH)CH_2OH)$]-Trp-Phe-[(R)-NH-CH($CH_2$-$C_6H_5$)-$CH_2$-NH]-} trifluoroacetic acid

(am) Cyclo{-Suc[1(S)-(3-carboxypropanoyl)amino]-Trp-Phe-[(R)-NH-CH($CH_2$-$C_6H_5$)-$CH_2$-NH]-}

(an) Cyclo{-Suc[1(S)-[3-N'-ß-D-glucopyranos-1-yl)-carboxamidopropanoyl]amino]-Trp-Phe-[(R)NH-CH($CH_2$-$C_6H_5$)-$CH_2$NH]-}

(ao) Cyclo{-Suc[1(S)-[(carboxymethyl)amino]-Trp-Phe-[(R)-NH-CH($CH_2$-$C_6H_5$)-$CH_2$-NH]-} trifluoroacetic acid

(ap) Cyclo{-Suc[1(S)-[N'-ß-D-glucopyranos-1-yl)-carboxyamideomethyl]amino]-Trp-Phe-[(R)-NH-CH($CH_2$-$C_6H_5$)-$CH_2$-NH]-} trifluoroacetic acid

(aq) Cyclo{-Suc[1(S)-(quinyl)amine]-Trp-Phe-[(R)-NH-CH($CH_2$-$C_6H_5$)-$CH_2$-NH]-}

(ar) Cyclo{-Suc[1(S)-(4-aminobutanoyl)amino]-Trp-Phe-[(R)-NH-CH($CH_2$-$C_6H_5$)-$CH_2$-NH]-} trifluoroacetic acid

(as) Cyclo{-Suc[1(S)-[1,4')bipiperidin-1-yl]acetamido]-Trp-Phe-[(R)-NH-CH($CH_2$-$C_6H_5$)-$CH_2$-NH]-} trifluoroacetic acid

(at) Cyclo{-Suc[1-N-(ß-D-glucopyranos-1-yl)-carboxyamido]-Trp-Phe-[(R)-NH-CH($CH_2$-$C_6H_5$)-$CH_2$-NH]-}

(au) Cyclo{-Suc[1(S)-[N'-(2-N-acetyl-ß-D-glucopyranos-1-yl)-carboxyamido]-Trp-Phe-[(R)-NH-CH($CH_2$-$C_6H_5$)-$CH_2$-NH]-}.

4. (canceled)

5. (previously amended) A composition comprising a compound of formula (I) according to Claim 1 in combination with a suitable carrier or excipient.

6. (currently amended) ~~Pharmaceutical~~ [[c]]Compositions according to Claim 5, to be used as tachykinin antagonists.

7. (currently amended) ~~Pharmaceutical~~ [[c]]Compositions according to Claim 6, to be used asantagonists of the human NK-2 receptor.

8. (canceled)

9. (canceled)

10. (canceled)

11. (previously amended) A method of inhibiting bronchoconstriction comprising administering a compound according to Claim 1 for a time and under conditions effective to antagonize NK-2 (neurokinin-2) receptors.

12. (previously amended) A method of inhibiting bronchoconstriction comprising administering a compound according to Claim 1 to a mammal afflicted with asthma for a time and under conditions effective to antagonize NK-2 receptors.

13. (previously amended) A method of inhibiting bronchoconstriction comprising administering a compound according to Claim 1 to a mammal afflicted with an anxiety

disorder for a time and under conditions effective to antagonize NK-2 receptors.

14. (currently amended) A method of inhibiting bronchoconstriction comprising administering quantities of between 0.02 and 10 mg/kg of body weight of active principle consisting of a compound ~~of formula (I),~~ according to Claim 1, to a patient afflicted with asthma, coughing, pulmonary irritation, intestinal spasms, spasms of the biliary tract, local spasms of the bladder and of the ~~uterer~~ ureter during cystitis[[, and]] or kidney infections and colics for a time and under conditions effective to antagonize NK-2 receptors.

15. (original) A mixture comprising two or more compounds according to claim 1.

16. (original) A method of inhibiting bronchoconstriction comprising administering a compound according to claim 1 for a time and under conditions effective to antagonize NK-2 receptors.

17. (original) A method of inhibiting bronchoconstriction comprising administering a compound according to claim 1 to a mammal in need thereof for a time and under conditions effective to antagonize NK-2 receptors.

18. (original) A method according to claim 17 wherein said mammal is afflicted with a disorder selected from the group consisting of the bronchospastic and inflammatory component of asthma, coughing, pulmonary irritation, intestinal spasms, spasms of the biliary tract, local